Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Omega Diagnostics shares rise as company reportedly selected to make Covid tests

Published 08/02/2021, 09:26
Updated 08/02/2021, 09:28
© Reuters.

© Reuters.

By Samuel Indyk

Investing.com – Omega Diagnostics Group Plc (LON:ODX), the UK-listed healthcare company, has reportedly been selected by the UK Department of Health to produce additional lateral flow tests, according to the Financial Times. Omega Diagnostics, alongside SureScreen and Global Access Diagnostics are said to have been chosen to produce up to 2mln lateral flow devices per day.

Commenting on the article in the FT, Omega confirmed they are continuing to modify its Alva-based facility to “significantly” upscale its lateral flow test production capacity but refrained from confirming a signed deal with the UK government. “When contracts or supply agreements are signed to utilise this capacity the Company will announce this in line with AIM disclosure obligations,” Omega said in a statement.

The government also announced that private company SureScreen had signed a deal to supply a further 20mln rapid lateral flow tests. The tests from SureScreen have been proven to detect the new B117 variant (the Kent variant) of the coronavirus and have been validated by Public Health England.

Accuracy of lateral flow tests

There have been some question marks over the accuracy of lateral flow tests with some suggestions they miss a high number of active infections, up to 60% in some cases. A recent feature in the BMJ suggested that the accuracy of the tests depends on several factors including the onset of infection, the concentration of the virus in the specimen, the quality of processing and the precise formulation of the reagents in the test kits.

Omega Diagnostics

At the time of writing, Omega Diagnostics trade higher by around 24% at 86.65p per share, at their highest level this year. However, shares are still off their all time high of 127p, hit in October last year.

Latest comments

The company has come out and denied it.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.